Show simple item record

dc.contributor.authorWang, Zhipeng
dc.contributor.authorTan, Jiao
dc.contributor.authorMcConville, Christopher
dc.contributor.authorKannappan, Vinodh
dc.contributor.authorTawari Patricia Erebi
dc.contributor.authorBrown, James
dc.contributor.authorDing, Jin
dc.contributor.authorArmesilla, Angel
dc.contributor.authorIrache, Juan M.
dc.contributor.authorMei, Qi-Bing
dc.contributor.authorTan, Yuhuan
dc.contributor.authorLiu, Ying
dc.contributor.authorJiang, Wenguo
dc.contributor.authorBian, Xiuwu
dc.contributor.authorWang, Weiguang
dc.date.accessioned2017-02-21T14:44:49Z
dc.date.available2017-02-21T14:44:49Z
dc.date.issued2016-08-10
dc.identifier.citationWang Z., Tan J., McConville C., Kannappan V., Tawari PE., Brown J., Ding J., Armesilla AL., Irache JM., Mei QB., Tan Y., Liu Y., Jiang W., Bian XW., Wang W. (2016) 'Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells', Nanomedicine: Nanotechnology, Biology and Medicine, 13 (2) pp. 641-657. doi: 10.1016/j.nano.2016.08.001
dc.identifier.issn1549-9634
dc.identifier.doi10.1016/j.nano.2016.08.001
dc.identifier.urihttp://hdl.handle.net/2436/620384
dc.description.abstractDisulfiram (DS), an anti-alcoholism drug, shows very strong cytotoxicity in many cancer types. However its clinical application in cancer treatment is limited by the very short half-life in the bloodstream. In this study, we developed a poly lactic-co-glycolic acid (PLGA)-encapsulated DS protecting DS from the degradation in the bloodstream. The newly developed DS-PLGA was characterized. The DS-PLGA has very satisfactory encapsulation efficiency, drug-loading content and controlled release rate in vitro. PLGA encapsulation extended the half-life of DS from shorter than 2 minutes to 7 hours in serum. In combination with copper, DS-PLGA significantly inhibited the liver cancer stem cell population. CI-isobologram showed a remarkable synergistic cytotoxicity between DS-PLGA and 5-FU or sorafenib. It also demonstrated very promising anticancer efficacy and antimetastatic effect in liver cancer mouse model. Both DS and PLGA are FDA approved products for clinical application. Our study may lead to repositioning of DS into liver cancer treatment.
dc.language.isoen
dc.publisherElsevier
dc.relation.urlhttp://www.sciencedirect.com/science/article/pii/S1549963416301083
dc.subjectDisulfiram
dc.subjectPLGA
dc.subjectLiver cancer
dc.subjectCancer stem cells
dc.subjectDrug repositioning
dc.subjectNano-technology
dc.subjectDrug delivery
dc.titlePoly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells
dc.typeJournal article
dc.identifier.journalNanomedicine: Nanotechnology, Biology and Medicine
dc.date.accepted2016-08-01
rioxxterms.funderJisc
rioxxterms.identifier.projectUoW210217WW
rioxxterms.versionAM
rioxxterms.licenseref.urihttps://creativecommons.org/CC BY-NC-ND 4.0
rioxxterms.licenseref.startdate2017-02-21
dc.source.volume13
dc.source.issue2
dc.source.beginpage641
dc.source.endpage657
refterms.dateFCD2018-09-27T12:00:11Z
refterms.versionFCDAM
refterms.dateFOA2017-02-21T00:00:00Z
html.description.abstractDisulfiram (DS), an anti-alcoholism drug, shows very strong cytotoxicity in many cancer types. However its clinical application in cancer treatment is limited by the very short half-life in the bloodstream. In this study, we developed a poly lactic-co-glycolic acid (PLGA)-encapsulated DS protecting DS from the degradation in the bloodstream. The newly developed DS-PLGA was characterized. The DS-PLGA has very satisfactory encapsulation efficiency, drug-loading content and controlled release rate in vitro. PLGA encapsulation extended the half-life of DS from shorter than 2 minutes to 7 hours in serum. In combination with copper, DS-PLGA significantly inhibited the liver cancer stem cell population. CI-isobologram showed a remarkable synergistic cytotoxicity between DS-PLGA and 5-FU or sorafenib. It also demonstrated very promising anticancer efficacy and antimetastatic effect in liver cancer mouse model. Both DS and PLGA are FDA approved products for clinical application. Our study may lead to repositioning of DS into liver cancer treatment.


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
1-s2.0-S1549963416301083-main.pdf
Size:
3.119Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/CC BY-NC-ND 4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/CC BY-NC-ND 4.0